Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
52 shown of 6,806 total abstracts
  1. Abstract 97972026-06-05 · 16:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-69
    H. Rugo, F. Andre, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  2. Abstract 104762026-06-01 · 18:00 CT · S406
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-742
    H. Borghaei, M.C. Garassino · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  3. Abstract 95942026-06-03 · 13:15 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Modi, R. Herbst · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  4. Abstract 100152026-06-02 · 20:15 CT · S100A
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-54
    J. Cortes, N. Rizvi, S. Tolaney, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  5. Abstract 98532026-06-03 · 16:45 CT · S406
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-365
    G. Curigliano, H. Borghaei, N. Rizvi, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  6. Abstract 101472026-06-04 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-801 study)
    P. Schmid, J. Cortes, S. Modi · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  7. Abstract 98252026-06-03 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-97
    E. Winer, S. Peters · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  8. Abstract 96572026-06-02 · 18:45 CT · S100A
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    H. Rugo, S. Modi, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  9. Abstract 96002026-06-05 · 14:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-84
    R. Herbst, J. Brahmer · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  10. Abstract 100832026-06-01 · 15:45 CT · S100A
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-104
    C. Robert, M. Reck, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  11. Abstract 104132026-06-04 · 21:45 CT · S406
    KEYNOTE-693: Keytruda (pembrolizumab) 1L in metastatic melanoma
    L. Paz-Ares, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  12. Abstract 99532026-06-01 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-590 study)
    T. Mok, G. Curigliano, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  13. Abstract 101602026-06-02 · 18:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    A. Spira, E. Winer, C. Saura · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  14. Abstract 104712026-06-01 · 13:15 CT · S100A
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-523
    M. Krop, T. Mok, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  15. Abstract 96362026-06-03 · 21:30 CT · Hall B1
    CheckMate-418: Opdivo (nivolumab) 3L+ in metastatic melanoma
    H. Borghaei, T. Mok, A. Spira · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  16. Abstract 97092026-06-03 · 18:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-319
    N. Rizvi, S. Modi, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  17. Abstract 97302026-06-05 · 15:45 CT · S100A
    KEYNOTE-52: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    M.C. Garassino, P. Schmid · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  18. Abstract 98892026-06-05 · 13:45 CT · Arie Crown Theater
    KEYNOTE-885: Keytruda (pembrolizumab) 1L in metastatic melanoma
    M.C. Garassino, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  19. Abstract 100812026-06-05 · 20:45 CT · Arie Crown Theater
    CheckMate-140: Opdivo (nivolumab) adjuvant in metastatic melanoma
    T. Mok, S. Peters, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  20. Abstract 102952026-06-04 · 16:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-123
    S. Peters, S. Antonia, T. Mok · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  21. Abstract 98642026-06-05 · 16:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-503
    M.C. Garassino, N. Rizvi · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  22. Abstract 99082026-06-03 · 15:00 CT · Arie Crown Theater
    KEYNOTE-805: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    S. Antonia, A. Spira, M. Krop, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  23. Abstract 104172026-06-01 · 21:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-495 study)
    H. Rugo, P. Schmid, S. Modi · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  24. Abstract 97342026-06-01 · 19:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-26
    C. Saura, N. Rizvi, M. Krop, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  25. Abstract 103992026-06-04 · 16:00 CT · S406
    KEYNOTE-83: Keytruda (pembrolizumab) 1L in metastatic melanoma
    N. Rizvi, H. Borghaei · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  26. Abstract 99362026-06-02 · 21:45 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    P. Schmid, N. Rizvi, C. Saura, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  27. Abstract 100852026-06-02 · 19:00 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-35
    S. Modi, C. Robert, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  28. Abstract 102472026-06-04 · 18:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-102
    T. Mok, E. Winer · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  29. Abstract 101592026-06-01 · 18:15 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-579 study)
    R. Herbst, E. Winer, N. Rizvi · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  30. Abstract 103792026-06-04 · 14:15 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-925 study)
    J. Cortes, T. Mok, S. Modi, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  31. Abstract 96972026-06-01 · 18:45 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-940 study)
    S. Modi, N. Rizvi, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  32. Abstract 104382026-06-01 · 14:30 CT · S100A
    KEYNOTE-34: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    M. Krop, S. Antonia, C. Saura, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  33. Abstract 98942026-06-05 · 14:00 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-907
    G. Curigliano, S. Tolaney, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  34. Abstract 97592026-06-04 · 16:15 CT · Hall B1
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-310
    J. Brahmer, P. Schmid, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  35. Abstract 104372026-06-05 · 16:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-230
    G. Curigliano, S. Tolaney, M. Reck · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  36. Abstract 102562026-06-05 · 13:00 CT · E450
    CheckMate-140: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    M. Reck, N. Rizvi, M. Krop, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  37. Abstract 95172026-06-01 · 21:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-897
    M. Reck, T. Mok · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  38. Abstract 95242026-06-03 · 18:30 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-229
    P. Schmid, M. Krop · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  39. Abstract 104772026-06-05 · 15:30 CT · S406
    CheckMate-48: Opdivo (nivolumab) 1L in metastatic melanoma
    S. Antonia, A. Spira, M.C. Garassino, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  40. Abstract 97222026-06-03 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-67
    F. Andre, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  41. Abstract 100252026-06-01 · 21:00 CT · S406
    KEYNOTE-910: Keytruda (pembrolizumab) 2L in metastatic melanoma
    T. Mok, S. Modi, A. Spira, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  42. Abstract 102952026-06-03 · 14:00 CT · S100A
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-288
    A. Spira, C. Robert, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  43. Abstract 102372026-06-02 · 14:00 CT · S406
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-452
    N. Rizvi, S. Peters, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  44. Abstract 102762026-06-04 · 21:45 CT · E450
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-179
    M. Reck, E. Winer, F. Andre · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  45. Abstract 100952026-06-02 · 14:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-258
    M. Krop, F. Andre · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  46. Abstract 98042026-06-05 · 18:45 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-280
    C. Saura, H. Borghaei, M. Reck · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  47. Abstract 101562026-06-02 · 20:15 CT · Hall B1
    KEYNOTE-714: Keytruda (pembrolizumab) 2L in metastatic melanoma
    R. Herbst, E. Winer, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  48. Abstract 95132026-06-01 · 13:00 CT · Arie Crown Theater
    KEYNOTE-696: Keytruda (pembrolizumab) 2L in metastatic melanoma
    J. Cortes, S. Modi, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  49. Abstract 101892026-06-05 · 13:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-256
    S. Peters, F. Andre, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  50. Abstract 100262026-06-04 · 19:00 CT · E450
    CheckMate-228: Opdivo (nivolumab) 1L in metastatic melanoma
    S. Tolaney, S. Antonia, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  51. Abstract 103812026-06-02 · 16:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-753
    S. Peters, S. Tolaney · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  52. Abstract 100632026-06-03 · 16:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-640
    S. Antonia, H. Borghaei · University of Chicago
    Poster SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.